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Imported Fatal 
Hantavirus 
Pulmonary 
Syndrome
To the Editor: Hantavirus pulmo-
nary syndrome (HPS) is characterized 
by fever, gastrointestinal symptoms, 
respiratory distress, elevated hemato-
crit, hypoalbuminemia, and thrombo-
cytopenia. Most cases in North Amer-
ica are acquired from rodent vectors 
and are caused by the Sin Nombre 
virus. Person-to-person transmission 
has been reported for Andes virus (1,2) 
but not for Sin Nombre virus (3). We 
describe a patient with fatal hantavirus 
pulmonary syndrome.
The patient was a previously 
healthy 15-year-old Canadian girl. In 
the spring of 2006, she had traveled to 
the Santa Cruz-San Jose de Chiquitas 
corridor of Bolivia with her parents 
and siblings for a 4-week visit (Fig-
ure), where they stayed with family 
and friends on their farms. The family 
noted rodent droppings outside but no 
rodents were seen. The patient had no 
known exposure to rodents or rodent 
droppings after her return to Canada.
On day 26 after her return from 
Bolivia, the patient sought treatment 
at a community hospital at 6:30 AM 
for malaise and mild fever. During the 
night before seeking treatment, she 
had mild confusion. Her initial blood 
pressure was 99/50, heart rate 97, and 
oxygen saturation 96% on room air. 
Her hemoglobin was 192 g/L (refer-
ence range 117–149), platelets 82 × 
109/L (reference range 165–400), and 
leukocyte count 7.5 × 109/L (reference 
range 3.9–10.2). She was initially 
treated with 3 liters of normal saline 
and repeat hemoglobin tests showed 
a value of 206 g/L. Due to ongoing 
hypotension and hypoxia, she was in-
tubated and sedated. Rocuronium was 
used as a paralytic agent to facilititate 
high pressure mechanical ventilation 
and maintain patient-ventilator syn-
chrony. Dopamine and epinephrine 
were given as intravenous drips. Ar-
rangements were made for the patient 
to be transferred to a tertiary pediatric 
care center for possible extracorporeal 
membrane oxygenation. During air 
transport, she had an asystolic cardiac 
arrest. While administering cardiopul-
monary resuscitation, members of the 
healthcare team were exposed to a con-
siderable volume of pulmonary edema 
ﬂ  uid expelled from the patient’s endo-
tracheal tube. Few, if any, were able 
to maintain adequate protection with 
face shields or protective eyewear. Re-
suscitation efforts were unsuccessful, 
and the patient was pronounced dead 
on arrival at the tertiary care center 
at 7:26 PM. Postmortem examination 
showed evidence of marked pulmo-
nary edema, diffuse alveolar damage, 
and lymphoid inﬂ  ammation in the pul-
monary interstitium. 
Serologic examination of an acute 
blood sample was immunoglobulin M 
(IgM) positive for Sin Nombre virus, 
but low optical densities indicated po-
tential for an infection with a related 
hantavirus rather than Sin Nombre 
virus. Subsequently, reverse transcrip-
tion–PCR (RT–PCR) on blood in 
EDTA and lung tissue followed by se-
quence analysis conﬁ  rmed an Andes-
like hantavirus infection. None of the 
40 household and healthcare contacts 
of the patient had symptoms com-
patible with HPS during an 8-week 
monitoring period. Two contacts with 
nonspeciﬁ  c symptoms were tested and 
found to be negative for hantavirus-
speciﬁ  c IgM and IgG and negative by 
RT-PCR. 
Additonally, a seroprevalence 
survey of close contacts and assess-
ment of level of contact was conduct-
ed. Close contacts were deﬁ  ned  as 
persons who lived in the same house-
hold as the patient, were in the same 
enclosed space for >2 hours, or pro-
vided healthcare to her while she was 
symptomatic. Twenty-eight (62%) 
of 45 close contacts provided serum 
over the next 5 months. All serum 
samples were negative for Sin Nom-
bre and Andes IgG and Sin Nombre 
IgM by ELISA. Fourteen (50%) of 
the 28 completed a self-administered 
questionnaire which assessed the type 
and intensity of contact. Of these, 12 
were healthcare workers and 2 were 
friends. One friend had contact with 
Figure. Map of Bolivia with an inset map of North America showing the location of British 
Columbia (BC) and its relation to Bolivia.LETTERS
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the patient 3 days before she died, a 
friend and a healthcare worker had 
contact with her on the day before her 
death, and the rest of the healthcare 
workers had contact with the patient 
on the day she died. 
To our knowledge, this is the ﬁ  rst 
imported case and the tenth case of 
HPS reported in British Columbia, 
Canada, since 1994 (2006 BC Annual 
Summary of Reportable Diseases, 
available from www.bccdc.org/con-
tent.php?item=33) (4). Six of these 
10 cases were fatal. All cases except 
the 1 described here have been lo-
cally acquired Sin Nombre infections. 
Sin Nombre virus is endemic in the 
Peromyscus maniculatus (deer mice) 
population in most of British Colum-
bia (5).
Worldwide, imported cases of 
HPS are unusual, although HPS has 
been reported in countries that are in 
close geographic proximity or in trav-
elers to disease-endemic areas (6–8). 
Fortunately, none of the persons ex-
posed to the patient reported symptoms 
consistent with HPS during the incuba-
tion period, and none who were tested 
seroconverted. Seroprevalence surveys 
in Chile among healthcare worker con-
tacts of patients with HPS caused by 
the Andes virus showed a prevalence 
of 0% (9). A report from Argentina 
showed that cases due to secondary 
transmission occurred mostly in non-
healthcare workers after prolonged 
close contact in the prodromal period 
(10). In conclusion, we describe an im-
ported case of fatal HPS due to an An-
des-like hantavirus with no evidence of 
secondary transmission.
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Bocavirus 
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To the Editor: Human bocavirus 
(HBoV) (1) is increasingly recognized 
as a cause of respiratory infections 
worldwide. Children and infants ap-
pear to be most at risk (2–7), although 
HBoV’s role in immunocompromised 
patients remains unclear. We report on 
a child with disseminated HBoV in-
fection after hematopoietic stem cell 
transplantation (HSCT). HBoV DNA 
was detected at high levels in naso-
pharyngeal aspirates (NPAs) and in 
blood and stool samples. 
A 4.5-year-old boy with dyskera-
tosis congenita was brought for treat-
ment to our hospital due to severe 
persistent cytopenia. Allogenic HSCT 
was performed in August 2006 after 
conditioning with total body irradia-
tion (200 cGy, day –8 before HSCT 
surgery), ﬂ  udarabine (days –7 to –4), 
antithymocyte globulin (days –4 to           
–1), and cyclophosphamide (days –3 